* Achillion announces initiation of patient dosing by
Janssen in a global, short treatment-duration phase 2B study of
JNJ-4178 in chronic HCV
The post BRIEF-Achillion announces initiation of patient dosing by Janssen in phase 2B study appeared first on NASDAQ.